Trevena, Inc.
TRVN Healthcare Biotechnology
Revenue growth for three consecutive years, operating cash flow growth for three.
Follow TRVN
Trevena, Inc. (TRVN) EV/Sales
As of 16 October 2026, Trevena, Inc. (TRVN) trades at a EV/Sales of 35.0×. Over the past ten years it has ranged from −40.8× (May 2023) to 221× (October 2021); the current reading is higher than 61% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 2.6× | (91.62%) |
| FY2022 | 31.4× | (49.47%) |
| FY2021 | 62.2× | 20.84% |
| FY2020 | 51.5× | 447.99% |
| FY2019 | 9.4× | — |
| FY2018 | −1.6× | — |
| FY2016 | 30.6× | (37.33%) |
| FY2015 | 48.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 40.9× | (12.13%) |
| Jun 2024 | 46.5× | 581.76% |
| Mar 2024 | 6.8× | 159.13% |
| Dec 2023 | 2.6× | 101.25% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −54.6× |
| BRTX Biorestorative Therapies, Inc. compare | −5.7× |
| CLSDQ Clearside Biomedical, Inc. compare | −1.2× |
| NEXI NexImmune, Inc. compare | n/m |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| OGEN Oragenics, Inc. compare | 3.6× |
| ITRMF Iterum Therapeutics PLC compare | 24.4× |
| TRVN Trevena, Inc. | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)